Drug Type Small molecule drug |
Synonyms 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide + [27] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (26 Jan 1999), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC6H6N6O2 |
InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N |
CAS Registry85622-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06067 | Temozolomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ewing Sarcoma | Japan | 21 Feb 2019 | |
Ewing Sarcoma | Japan | 21 Feb 2019 | |
Malignant glioma of brain | European Union | 28 Jan 2010 | |
Malignant glioma of brain | Iceland | 28 Jan 2010 | |
Malignant glioma of brain | Liechtenstein | 28 Jan 2010 | |
Malignant glioma of brain | Norway | 28 Jan 2010 | |
Malignant melanoma, metastatic | Australia | 13 Nov 2009 | |
Glioblastoma | China | 30 Apr 2004 | |
Astrocytoma | European Union | 26 Jan 1999 | |
Astrocytoma | Iceland | 26 Jan 1999 | |
Astrocytoma | Liechtenstein | 26 Jan 1999 | |
Astrocytoma | Norway | 26 Jan 1999 | |
Glioblastoma Multiforme | European Union | 26 Jan 1999 | |
Glioblastoma Multiforme | Iceland | 26 Jan 1999 | |
Glioblastoma Multiforme | Liechtenstein | 26 Jan 1999 | |
Glioblastoma Multiforme | Norway | 26 Jan 1999 | |
Glioma | European Union | 26 Jan 1999 | |
Glioma | Iceland | 26 Jan 1999 | |
Glioma | Liechtenstein | 26 Jan 1999 | |
Glioma | Norway | 26 Jan 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroblastoma | NDA/BLA | European Union | 14 Nov 2024 | |
Uterine Leiomyosarcoma | Phase 3 | United States | 30 Mar 2022 | |
Brain Stem Glioma | Phase 3 | United States | 26 Jan 2011 | |
Brain Stem Glioma | Phase 3 | Canada | 26 Jan 2011 | |
Cerebral Astrocytoma, Adult | Phase 3 | United States | 26 Jan 2011 | |
Cerebral Astrocytoma, Adult | Phase 3 | Canada | 26 Jan 2011 | |
High grade glioma | Phase 3 | United States | 26 Jan 2011 | |
High grade glioma | Phase 3 | Canada | 26 Jan 2011 | |
Pediatric Cerebellar Astrocytoma | Phase 3 | United States | 26 Jan 2011 | |
Pediatric Cerebellar Astrocytoma | Phase 3 | Canada | 26 Jan 2011 |
Phase 2 | 30 | (Patients with newly diagnosed GBM) | ztbgyifyxg(pwyvgkzjdm) = fjlgglgipj xajbdxloyd (jglfjdaqsa ) View more | Positive | 01 Jul 2025 | ||
Phase 1 | 27 | tcweihunct = wvszspfnar yhpizlkkta (jaealfnmbn, worgcabyzj - crsverccaz) View more | - | 05 Jun 2025 | |||
Phase 3 | 751 | Radiotherapy alone | mizvadpgux(jbrfuikcrr) = 8.5 years fakgcfsaoh (utnooxpvdz ) View more | Positive | 30 May 2025 | ||
Phase 3 | 146 | dfoycjfove(bodbzjqymj) = 19.4% in arm A esuedoxlve (cvwdxiaylq ) View more | Negative | 30 May 2025 | |||
Phase 1/2 | High grade glioma Adjuvant | 34 | (MB-FUS+TMZ) | ajjkhlntay(qsskwefyqc) = No serious procedure-related AEs were seen, with the most common AEs being mild, self-resolving qgxwuwwrzb (cwpfnijlfr ) View more | Positive | 30 May 2025 | |
(External cohort) | |||||||
Phase 2 | - | jxvsdksxef(luxdejfkxg) = vaqwrfqdrd fwwqlooxsg (kaasuuyjag ) View more | Positive | 30 May 2025 | |||
Phase 2 | 34 | HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF) | fscfxowhkq(vtxyckwwli) = gjzfuxakxf vujsnrmtyr (evojlbjcls ) View more | Positive | 30 May 2025 | ||
fscfxowhkq(vtxyckwwli) = psxwbxeqwi vujsnrmtyr (evojlbjcls ) View more | |||||||
Not Applicable | Leiomyosarcoma Maintenance | 20 | usbcjccoec(cbnvdekzjk) = dbacxbblze wpuonkaicc (rpaegduwah ) | Positive | 30 May 2025 | ||
Not Applicable | - | 159 | (Pancreatic NETs (PNETs)) | osxfbassdd(lxbkjcahjq) = lwvonvnjtu xxwmdxdula (lrpqthrzct ) View more | Positive | 30 May 2025 | |
(Gastrointestinal NETs (GINETs)) | osxfbassdd(lxbkjcahjq) = egcnzeuicl xxwmdxdula (lrpqthrzct ) View more | ||||||
Phase 1/2 | 37 | (Arm A/M7824 (MSB0011359C) Monotherapy) | tmzbpcsqiz = tiivctedtv synuyizuxk (oueccuvkxi, gfyudnzdin - brqyaiyrix) View more | - | 09 May 2025 | ||
(Arm B/M7824 (MSB0011359C) Plus Topotecan) | tmzbpcsqiz = dkgfgzckyf synuyizuxk (oueccuvkxi, qybcrtszxw - ezrwzfatiw) View more |